Sugi Predict

Sugi Predict / Compounds / SCHEMBL1648901

SCHEMBL1648901

SCHEMBL1648901

O=C(O)Cc1ccc2c(c1)[nH]c1ccccc12

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.74
▸ ALDH1A1 P00352 4/20 0.74
▸ MAPT P10636 2/20 0.67
▸ HPGD P15428 2/20 0.67
▸ HSD17B10 Q99714 2/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ KIF11 P52732 2/20 0.60
▸ PPARG P37231 3/20 0.53
▸ AKR1B1 P15121 1/20 0.53
▸ GAA P10253 1/20 0.51
▸ CASP1 P29466 1/20 0.51
▸ CASP7 P55210 1/20 0.51
▸ EGFR P00533 2/20 0.50
▸ AHR P35869 1/20 0.50
▸ IMPDH2 P12268 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL8206725 0.98 KDM4E (0.72) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL31324185 0.90 KDM4E (0.83) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL18938363 0.90 KDM4E (0.83) KDM4EALDH1A1MAPTHPGDHSD17B10
Carbazole SCHEMBL30528384 0.86 AKR1B1 (0.65) KDM4EALDH1A1MAPTHPGDHSD17B10
Carbazole SCHEMBL30528387 0.85 ALDH1A1 (0.56) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL29606312 0.85 KDM4E (1.00) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL27471515 0.85 KDM4E (1.00) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL30927850 0.84 KDM4E (0.61) KDM4EALDH1A1MEN1KMT2AKIF11
SCHEMBL30419824 0.84 KDM4E (0.61) KDM4EALDH1A1MEN1KMT2AKIF11
Carbazole SCHEMBL30528390 0.82 ALDH1A1 (0.56) KDM4EALDH1A1MAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103705496-B Positively charged water-soluble prodrugs of aryl and heteroaryl propionic acids with fast skin penetration rate 于崇曦 2017-03-01 — — CN claimed
WO-2022103149-A1 NOVEL CARBAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 큐라클 2022-05-19 — — WO disclosed
WO-2022103149-A1 NOVEL CARBAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 큐라클 2022-05-19 — — WO disclosed
CN-108451957-A Purposes of the 3- acetyl group -11- keto-beta-boswellic acids in preparing treatment Periprosthetic bone dissolving drug 苏州大学附属第医院 2018-08-28 — — CN disclosed
US-9872846-B2 High penetration compositions and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2018-01-23 — — US disclosed
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2017-07-27 — — US disclosed
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2017-07-27 — — US disclosed
CN-103705496-B Positively charged water-soluble prodrugs of aryl and heteroaryl propionic acids with fast skin penetration rate 于崇曦 2017-03-01 — — CN disclosed
EP-2852572-A1 CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION Eli Lilly and Company (US) 2015-04-01 — — EP disclosed
WO-2013176698-A1 CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION ELI LILLY AND COMPANY (US) 2013-11-28 — — WO disclosed
CN-103415286-A Compounds and methods for treating pain AKRON MOLECULES GMBH 2013-11-27 — — CN disclosed
CN-101506161-B Positively charged water-soluble prodrugs of aryl and heteroaryl propionic acids with fast skin penetration rate YU CHONGXI 2013-11-13 — — CN disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 — — US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 — — US disclosed
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO., LTD. (CN) 2009-09-24 — — US disclosed
EP-0970694-B1 Use of carprofen and derivatives therof for treating or preventing articular degeneration PFIZER PROD INC (US) 2006-07-05 — — EP disclosed
US-5877199-A ALZHEIMER'S DISEASE; SEDATIVE SANKYO COMPANY, LIMITED (JP) 1999-03-02 — — US disclosed
EP-0804416-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY LIMITED (JP) 1997-11-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES KDM4E 4795/4885ALDH1A1 1790/4885MAPT 3194/4885
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES KDM4E 4795/4885ALDH1A1 1790/4885MAPT 3194/4885
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES KDM4E 4795/4885ALDH1A1 1790/4885MAPT 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.